Molecular Name

Target point

Molecular model

Indication

Development stage

Catumaxomab [15] {!!! INVALID CITATION !!! , #0;Knodler, 2018 #10} {!!! INVALID CITATION !!! , #0;Knodler, 2018 #11}

EPCAM + CD3

TrioMab

Malignant ascites

Approved

MT110 [16]

EPCAM + CD3

BiTE

Colorectal cancer

Phase I

Blinatumomab [17]

CD19 + CD3

BiTE

Acute myeloid leukemia

Approved

MT111 [18]

CEA + CD3

BiTE

Gastric adenocarcinoma

Phase I

MGD006 [19]

CD123 + CD3

DART

Acute myeloid leukemia

Phase I

MGD007 [20]

GPA33 + CD3

DART

colorectal cancer

Phase I

AFM11 [21]

CD3 + CD19

TandAb

Non-Hodgkin’s lymphoma

Phase I

AFM13 [22]

CD30 + CD16

TandAb

Hodgkin’s lymphoma

Phase I

RG7221

Ang-2 + VEF

CrossMab

colorectal cancer

Phase II

RG7802 [23]

CEA + CD3

CrossMab

Solid tumor

Phase I